Skip to content

Study · Measured the body's own peptide · 1992

2 results

Neurohypophyseal and pituitary-adrenocortical responses to the alpha 1 agonist methoxamine in humans.

Radant A, Peskind ER, Wilkinson CW, Veith RC, Dorsa DM, Leake RD, Ervin MG, Raskind MA

Neuroendocrinology1 Apr 1992Cited by 5 (Europe PMC)

PMID1314337 (opens in a new tab)DOI10.1159/000126145 (opens in a new tab)PepBankPUB-01314337
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelNon-randomized trialMechanism

    In humans, intravenous methoxamine did not change plasma levels of the body's own oxytocin.

    In plain wordsIn people, methoxamine did not change the body's own oxytocin in blood.

    Peptide
    Oxytocin
    Outcome
    No significant changePlasma oxytocin response to methoxamine
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Source sentences

    Summary
    Neither methoxamine nor NE affected plasma OT.
    1 context sentence
    Summary · context
    To test the hypothesis that the release of neurohypophyseal peptides into plasma in humans is stimulated by a central nervous system (CNS) alpha 1 adrenergic mechanism, we measured the responses of arginine vasopressin (AVP) and oxytocin (OT) to intravenous methoxamine, an alpha 1 agonist which ente…

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelNon-randomized trialMechanism

    In humans, intravenous norepinephrine did not change plasma levels of the body's own oxytocin.

    In plain wordsIn people, norepinephrine did not change the body's own oxytocin in blood.

    Peptide
    Oxytocin
    Outcome
    No significant changePlasma oxytocin response to norepinephrine
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Source sentences

    Summary
    Neither methoxamine nor NE affected plasma OT.
    1 context sentence
    Summary · context
    To test the hypothesis that the release of neurohypophyseal peptides into plasma in humans is stimulated by a central nervous system (CNS) alpha 1 adrenergic mechanism, we measured the responses of arginine vasopressin (AVP) and oxytocin (OT) to intravenous methoxamine, an alpha 1 agonist which ente…

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:54 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.